News|Articles|November 17, 2026

FDA approves adrabetadex for infantile-onset Niemann-Pick type C

Fact checked by: Benjamin P. Saylor

Key Takeaways

  • Adrabetadex (Lembaz) is FDA approved to reduce the risk of death in patients weighing at least 7 kg with NPC whose neurologic symptoms began before age 6 years. It is given by intrathecal injection.
  • Approval was based on a 55% lower risk of death compared with matched external controls, not on a randomized trial.
SHOW MORE

The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.

The FDA approved adrabetadex (Lembaz; Beren Therapeutics) on November 17, 2026, to reduce the risk of death in adults and children who weigh at least 7 kg and have Niemann-Pick disease type C (NPC) with neurologic symptoms that began before age 6 years.¹ The drug is given by intrathecal injection and carries a boxed warning for hearing impairment, including permanent hearing loss.¹

"Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical," said Elizabeth M. Berry-Kravis, MD, PhD, professor of pediatrics and neurological sciences at Rush University Medical Center and lead investigator for the drug's expanded access program.¹ "For the first time, LEMBAZ gives clinicians a way to address the underlying cholesterol trafficking defect that causes infantile-onset NPC, where early intervention can make the greatest difference."¹

Adrabetadex survival data supporting FDA approval in infantile-onset NPC

Approval was based on an analysis of overall survival in patients with infantile-onset NPC who received adrabetadex in 3 clinical studies and an expanded access program, compared with matched external controls.¹ The FDA determined that this comparison served as the adequate and well-controlled study supporting approval.¹ Treatment was associated with a 55% reduction in the risk of death.¹ The company's announcement did not report patient numbers, length of follow-up, or confidence intervals.¹

An earlier survival analysis, presented in March 2026, compared 72 treated children with 119 matched controls and reported a 71% lower risk of death and 5-year survival of 84% vs 42%.² That analysis differs from the one reflected in the approval.¹,²

Boxed warning and hearing monitoring with intrathecal adrabetadex

Permanent hearing impairment ranging from mild to profound has occurred with treatment, including in some patients whose hearing was normal before treatment.¹ A baseline audiology evaluation, including pure tone audiometry, speech recognition testing, and tympanometry, is required before the first dose, and repeat results guide dosing.¹ Hearing is retested 1 to 2 weeks after the first and second doses at each dosage level, then monthly once the dose is stable until 3 results in a row are stable, and every 12 months after that.¹ The dose is not increased if hearing loss exceeds set limits, and it is not known whether continuing or lowering the dose affects the risk of further loss.¹

Ataxia and fatigue may occur in the first few days after a dose and have led to hospitalization.¹ Adverse reactions reported in at least 25% of patients in a clinical trial were hearing impairment, ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.¹

Burden of infantile-onset Niemann-Pick disease type C in children

NPC is an autosomal recessive disorder caused by variants in the NPC1 gene, which account for about 95% of cases, or the NPC2 gene.³ About 475 children in the US, roughly half of all people with NPC, have the infantile-onset form.¹ Mean age at death is about 5.6 years when neurologic symptoms begin before age 2 years and about 13.4 years when they begin between ages 2 and 6 years.¹

In 2024, the FDA approved arimoclomol, used with miglustat, for neurologic manifestations of NPC in adults and children aged 2 years and older.⁴

Adrabetadex mechanism and FDA regulatory history

Adrabetadex is a mixture of 2-hydroxypropyl-β-cyclodextrin compounds that helps move cholesterol trapped inside brain cells to where cells can use it.¹,³ The FDA granted the drug breakthrough therapy designation in 2016 under a previous sponsor but rescinded it based on data from a 12-month phase 2b/3 trial, then granted the designation again in 2025.³

"We appreciate the close collaboration with the FDA over the last 5 years to develop a rigorous approach to evaluating more than a decade of clinical evidence," said Jason Camm, chief executive officer of Beren Therapeutics.¹

Beren said the drug will be available at treatment sites nationwide in early December.¹

Limitations of the adrabetadex approval data

The approval rests on a comparison with external rather than randomized controls.¹ Patients in historical datasets may differ from treated patients in ways that matching cannot fully address. The only randomized trial lasted 12 months, and its results led the FDA to rescind the drug's first breakthrough designation.³

References
1. Beren Therapeutics. Beren Therapeutics announces U.S. FDA approval of LEMBAZ (adrabetadex), first & only medicine to improve survival in infantile-onset Niemann-Pick disease, type C. News release. Business Wire. November 17, 2026. Accessed November 17, 2026. https://www.businesswire.com/news/home/20261116327767/en/
2. Beren Therapeutics. Beren Therapeutics presents data supporting the efficacy of adrabetadex in infantile-onset NPC at 2026 ACMG Clinical Genetics Meeting. News release. Business Wire. March 12, 2026. Accessed November 16, 2026. https://www.businesswire.com/news/home/20260312378907/en
3. Beren Therapeutics. FDA grants breakthrough therapy designation to investigational drug adrabetadex for individuals with infantile-onset Niemann-Pick disease type C. News release. Business Wire. December 9, 2025. Accessed November 16, 2026. https://www.businesswire.com/news/home/20251209951827/en
4. US Food and Drug Administration. FDA approves first treatment for Niemann-Pick disease, type C. News release. September 20, 2024. Accessed November 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c

Related to this article